Abstract:Women with the apolipoprotein E e4/e4 genotype who have used hormone replacement therapy (HRT) showed 1.82% lower hippocampal, 2.4% lower parahippocampal and 1.24% lower thalamus volumes than those who have the e3/e3 genotype and had never used HRT. Differences in hippocampal volume are equivalent to approximately 1–2 years of hippocampal atrophy observed in typical health ageing trajectories in midlife (i.e. 0.98%–1.41% per year). Global prevalence of Alzheimer's Disease has a strong sex bias, with women representing approximately two‐thirds of the patients. Yet, the role of sex‐specific risk factors during midlife, including hormone replacement therapy (HRT) and their interaction with other major risk factors for Alzheimer's Disease, such as apolipoprotein E (APOE)‐e4 genotype and age, on brain health remains unclear. We investigated the relationship between HRT (i.e., use, age of initiation and duration of use) and brain health (i.e., cognition and regional brain volumes). We then consider the multiplicative effects of HRT and APOE status (i.e., e2/e2, e2/e3, e3/e3, e3/e4 and e4/e4) via a two‐way interaction and subsequently age of participants via a three‐way interaction. Women from the UK Biobank with no self‐reported neurological conditions were included (N = 207,595 women, mean age = 56.25 years, standard deviation = 8.01 years). Generalised linear regression models were computed to quantify the cross‐sectional association between HRT and brain health, while controlling for APOE status, age, time since attending centre for completing brain health measure, surgical menopause status, smoking history, body mass index, education, physical activity, alcohol use, ethnicity, socioeconomic status, vascular/heart problems and diabetes diagnosed by doctor. Analyses of structural brain regions further controlled for scanner site. All brain volumes were normalised for head size. Two‐way interactions between HRT and APOE status were modelled, in addition to three‐way interactions including age. Results showed that women with the e4/e4 genotype who have used HRT had 1.82% lower hippocampal, 2.4% lower parahippocampal and 1.24% lower thalamus volumes than those with the e3/e3 genotype who had never used HRT. However, this interaction was not detected for measures of cognition. No clinically meaningful three‐way interaction between APOE, HRT and age was detected when interpreted relative to the scales of the cognitive measures used and normative models of ageing for brain volumes in this sample. Differences in hippocampal volume between women with the e4/e4 genotype who have used HRT and those with the e3/e3 genotype who had never used HRT are equivalent to approximately 1–2 years of hippocampal atrophy observed in typical health ageing trajectories in midlife (i.e., 0.98%–1.41% per year). Effect sizes were consistent within APOE e4/e4 group post hoc sensitivity analyses, suggesting observed effects were not solely driven by APOE status and may, in part, be attributed to HRT use. Although, the design of this study means we cannot exclude the possibility that women who have used HRT may have a predisposition for poorer brain health.

Women's brain aging: Effects of sex‐hormone exposure, pregnancies, and genetic risk for Alzheimer's disease

Endogenous and Exogenous Estrogen Exposures: How Women’s Reproductive Health Can Drive Brain Aging and Inform Alzheimer’s Prevention

Investigating the synergistic effects of hormone replacement therapy, apolipoprotein E and age on brain health in the UK Biobank

Longitudinal associations of reproductive factors and exogeneous estrogens with neuroimaging biomarkers of Alzheimer's disease and cerebrovascular disease

Hormone Replacement Therapy and Alzheimer's Disease: Current State of Knowledge and Implications for Clinical Use

Impact of sex and APOE-ε4 genotype on patterns of regional brain atrophy in Alzheimer's disease and healthy aging

Menopausal hormone therapy and the female brain: leveraging neuroimaging and prescription registry data from the UK Biobank cohort.

Elevated gonadotropin levels are associated with increased biomarker risk of Alzheimer's disease in midlife women

Influence of the Onset of Menopause on the Risk of Developing Alzheimer's Disease

The Interaction Effects of Age, APOE and Common Environmental Risk Factors on Human Brain Structure

Hormone therapy is associated with lower Alzheimer's disease tau biomarkers in post-menopausal females -evidence from two independent cohorts

A Case for Estradiol: Younger Brains in Women with Earlier Menarche and Later Menopause

Age of menopause and dementia risk in 10,832 women from the Swedish Twin Registry

Sex-Dependent Effects of Cardiometabolic Health and APOE4 on Brain Age: A Longitudinal Cohort Study

Sex and menopause impact 31P-Magnetic Resonance Spectroscopy brain mitochondrial function in association with 11C-PiB PET amyloid-beta load

Gender differences in the moderating capacity of reserve and resilience factors on the association of Alzheimer’s disease brain pathology and cognitive function

Associations of endogenous estrogens, plasma Alzheimer's disease biomarkers, and APOE4 carrier status on regional brain volumes in postmenopausal women

Women’s Brain Health: Midlife Ovarian Removal Affects Associative Memory

Association of Reproductive Factors with Dementia: A Systematic Review and Dose-Response Meta-Analyses of Observational Studies

Reproductive Health Data and Its Relationship to Baseline Brain Imaging and Cognitive Measurements in Cognitively Unimpaired Female PSEN1 E280A Mutation Carriers and Non‐carriers from the API ADAD Trial

The Effects of Estrogen on the Risk of Developing Dementia: A Cohort Study Using the UK Biobank Data